<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02941679</url>
  </required_header>
  <id_info>
    <org_study_id>HM-FLUT-301</org_study_id>
    <nct_id>NCT02941679</nct_id>
  </id_info>
  <brief_title>Clinical Efficacy and Safety Evaluation of HCP1202 in COPD Patients</brief_title>
  <official_title>A 24-week, Randomized, Double-Blind, Active-controlled, Parallel Study of HCP1202 Combination Product, HGP1011, and HCP0910 in Treatment of Subjects With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 3 study to evaluate efficacy and safety of HCP1202
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed as a multi-center, double-blinded, randomized, phase 3 clinical trial
      to evaluate the efficacy and safety of HCP1202 compared to either treatment with HGP1011 or
      HCP0910 in COPD patients.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Trough FEV1 at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Trough FEV1 at Week 4 &amp; 8</measure>
    <time_frame>Baseline, Week 4, Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Trough FVC at Week 4 &amp; 8 &amp; 12</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Trough FEV1/FVC at Week 4 &amp; 8 &amp; 12</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transition Dyspnea Index scores at Week 4 &amp; 8 &amp; 12</measure>
    <time_frame>Week 4, Week 8, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Total SGRQ-C (St. George's Respiratory Questionnaire for COPD patients) and sectional scores at Week 4 &amp; 8 &amp; 12</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage (%) of Subjects Experienced with Moderate to Severe COPD Exacerbation from Baseline to Week 12</measure>
    <time_frame>Baseline through Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Occurrences in Moderate to Severe COPD Exacerbation per Subject from Baseline to Week 12</measure>
    <time_frame>Baseline through Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Amount of Rescue Medication Used per Subject from Baseline to Week 12</measure>
    <time_frame>Baseline through Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Daily Use of Rescue Medication per Subject from Baseline to Week 12</measure>
    <time_frame>Baseline through Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">252</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>HCP1202</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HGP1011</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCP0910</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCP1202</intervention_name>
    <description>Hanmi Pharmaceutical. Co., Ltd.</description>
    <arm_group_label>HCP1202</arm_group_label>
    <other_name>HCP1202 Capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HGP1011</intervention_name>
    <description>Boehringer Ingelheim</description>
    <arm_group_label>HGP1011</arm_group_label>
    <other_name>HGP1011 Capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCP0910</intervention_name>
    <description>GlaxoSmithKline</description>
    <arm_group_label>HCP0910</arm_group_label>
    <other_name>HCP0910 Capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female adults aged ≥ 40 years.

          -  Patients diagnosed with COPD.

          -  Patients with FEV1/FVC &lt; 0.7 at screening.

          -  Patients with a post-bronchodilator FEV1 &lt; 60% of the predicted normal OR Patients
             with a post-bronchodilator FEV1 &lt; 80% of the predicted normal if COPD exacerbation is
             moderate or worse developed at least twice within the past year or hospitalization
             occurred at least once within the past year due to COPD exacerbation.

          -  Patients with COPD Assessment Test ≥ 10.

          -  Patients with a history (current or ex-smokers) of smoking 10 pack-years or more (e.g.
             10 pack years = 1 pack/day x 10 years, or ½ pack/day x 20 years).

          -  Patients who understand the process of clinical trial and signed written informed
             consent.

        Exclusion Criteria:

          -  Patients with a current diagnosis of asthma.

          -  Patients with the following lung disorders that can affect the clinical trial, except
             for COPD: lung cancer, interstitial lung disease, thromboembolic pulmonary disease,
             moderate to severe bronchiectasis, sarcoidosis, pulmonary fibrosis, pulmonary
             hypertension, active tuberculosis, clinically significant tuberculous destroyed lung,
             alpha1-antitrypsin deficiency, etc.

          -  Patients underwent pulmonary lobectomy or lung volume reduction surgery within the
             past year.

          -  Patients who developed COPD exacerbation where antibiotics and/or systemic
             corticosteroids and/or hospitalization is advisable within 4 weeks prior to Visit 1 or
             during Run-in period (but, re-screening is possible 4 weeks after resolution of the
             COPD exacerbation occurred within 4 weeks prior to Visit 1).

          -  Patients who administered antibiotics for lower respiratory infection within 4 weeks
             prior to Visit 1 or during Run-in period (but, re-screening is possible 4 weeks after
             resolution of COPD exacerbation occurred within 4 weeks prior to Visit 1).

          -  Patients who have changed the COPD treatment method within 12 weeks prior to Visit 1
             (but, PDE4 inhibitor can be used until 4 weeks prior to Visit 1).

          -  Patients administered systemic corticosteroids within 4 weeks prior to Visit 1.

          -  Patients with the following clinically significant cardiovascular diseases: a history
             of myocardial infarction or unstable angina within 6 months prior to Visit 1, a
             history of unstable arrhythmia where its therapy method has been changed within 1 year
             prior to Visit 1, a history of hospitalization from NYHA Class III-IV heart failure, a
             history of atrial fibrillation, negative cardiac tachycardia, and/or hypertrophic
             cardiomyopathy.

          -  Patients with a history of long QTc syndrome.

          -  Patients with the clinical significance of ECG abnormality at screening (QTc(F) ≥ 470
             ms).

          -  Patients who require long-term oxygen therapy for more than 12 hours a day.

          -  Patients participated in acute respiratory rehabilitation within 6 months prior to
             Visit 1 (except for the patients under stabilized respiratory rehabilitation therapy
             of at least 6 weeks).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HyoungKyu Yoon, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yeouido St. Mary's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>HyoungKyu Yoon, M.D., Ph.D.</last_name>
    <email>cmcyhg@catholic.ac.kr</email>
  </overall_contact>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2016</study_first_submitted>
  <study_first_submitted_qc>October 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2016</study_first_posted>
  <last_update_submitted>October 19, 2016</last_update_submitted>
  <last_update_submitted_qc>October 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

